The Dayton Clinical Oncology Program (DCOP) was incorporated in the State of Ohio in 1982 as a non-profit 501 C-3 corporation. A Consortium Agreement was established between DCOP, the Dayton Area hospitals (all except Children's Medical Center), and Wright State University (WSU). A governing board was established, and corporate bylaws were developed. Currently, DCOP has an elected Board of Trustees with Howard M. Gross, M.D., DCOP Principal Investigator, as Chairperson of the Board, Stuart Merl, M.D., Associate Principal Investigator, as Vice Chairperson, Sidney J. Pinkus, MBA, Chief Executive Officer of DCOP, as President of the Board, and 15 other Trustees representing the 13 member hospitals, WSU, and at-large community members of our service area. The Board meets quarterly to review budget reports and program activities. Since 1982, DCOP has successfully applied for and received funding from NCI as a CCOP. We are currently seeking continued funding through the fiscal year ending May 31, 2014. Our current staff includes 16 Oncology Research Nurses funded by our member hospitals, and 16 office staff funded by the grant, including directors for quality, regulatory, and prevention, quality coordinator, data coordinator, research manager, data managers, administrative assistant, research associates, and research coordinators. Our current active physician Co Investigators total 74, representing our 13 hospitals and various specialties including oncology, radiation therapy, urology, surgery, gynecology, pulmonary and gastroenterology. WSU has been providing personnel, payroll, and accounting services support through a sub-contracting relationship established on December 23, 2001, when the grant was transferred from former fiscal agent Kettering Medical Center to DCOP. DCOP has continued as the grantee organization since that date.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
St Germain, Diane
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dayton Clinical Oncology Program
United States
Zip Code
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8

Showing the most recent 10 out of 201 publications